Cargando…
The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma
Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Although a few prognostic models of PTCL ha...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555175/ https://www.ncbi.nlm.nih.gov/pubmed/34715862 http://dx.doi.org/10.1186/s12935-021-02275-2 |
_version_ | 1784591924178452480 |
---|---|
author | Zhang, Yan Shi, Yuanfei Shen, Huafei Shou, Lihong Fang, Qiu Zheng, Xiaolong Zhu, Mingyu Huang, Xin Huang, Jiansong Li, Li Zhou, De Zhu, Lixia Zhu, Jingjing Ye, Xiujin Jin, Jie Xie, Wanzhuo |
author_facet | Zhang, Yan Shi, Yuanfei Shen, Huafei Shou, Lihong Fang, Qiu Zheng, Xiaolong Zhu, Mingyu Huang, Xin Huang, Jiansong Li, Li Zhou, De Zhu, Lixia Zhu, Jingjing Ye, Xiujin Jin, Jie Xie, Wanzhuo |
author_sort | Zhang, Yan |
collection | PubMed |
description | Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Although a few prognostic models of PTCL have been established in retrospective studies, some high-risk patients still can not be screened out. Therefor we retrospectively studied 347 newly diagnosed PTCL patients and assessed the prognostic role of lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) in the complete response (CR) and survival of PTCL patients. Patients with LMR ≤ 1.68 and PMR ≤ 300 achieved a lower CR rate and a poor survival. In multivariate analysis, LMR ≤ 1.68 (HR = 1.751, 95% CI 1.158–2.647, p < 0.05) and PMR ≤ 300 (HR = 1.762, 95% CI 1.201–2.586, p < 0.05) were independently associated with short survival. On this basis, a new prognostic model of PTCL was established to screen out high-risk patients. In our "Peripheral Blood Score (PBS)" model, three groups were identified at low risk (178 patients, 51.3%, score 0), intermediate risk (85 patients, 24.5%, score 1), and high risk (84 patients, 24.2%, score 2), having a 1-year OS of 86%, 55.3% and 22.6% (p < 0.05), and a 3-year OS of 43.4%, 20% and 13.1% (p < 0.05), respectively. Optimal strategies for identifying high-risk patients with PTCL are urgently needed. Our new PBS model is simple, inexpensive and widely available to screen out the high risk patients. |
format | Online Article Text |
id | pubmed-8555175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85551752021-10-29 The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma Zhang, Yan Shi, Yuanfei Shen, Huafei Shou, Lihong Fang, Qiu Zheng, Xiaolong Zhu, Mingyu Huang, Xin Huang, Jiansong Li, Li Zhou, De Zhu, Lixia Zhu, Jingjing Ye, Xiujin Jin, Jie Xie, Wanzhuo Cancer Cell Int Primary Research Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Although a few prognostic models of PTCL have been established in retrospective studies, some high-risk patients still can not be screened out. Therefor we retrospectively studied 347 newly diagnosed PTCL patients and assessed the prognostic role of lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) in the complete response (CR) and survival of PTCL patients. Patients with LMR ≤ 1.68 and PMR ≤ 300 achieved a lower CR rate and a poor survival. In multivariate analysis, LMR ≤ 1.68 (HR = 1.751, 95% CI 1.158–2.647, p < 0.05) and PMR ≤ 300 (HR = 1.762, 95% CI 1.201–2.586, p < 0.05) were independently associated with short survival. On this basis, a new prognostic model of PTCL was established to screen out high-risk patients. In our "Peripheral Blood Score (PBS)" model, three groups were identified at low risk (178 patients, 51.3%, score 0), intermediate risk (85 patients, 24.5%, score 1), and high risk (84 patients, 24.2%, score 2), having a 1-year OS of 86%, 55.3% and 22.6% (p < 0.05), and a 3-year OS of 43.4%, 20% and 13.1% (p < 0.05), respectively. Optimal strategies for identifying high-risk patients with PTCL are urgently needed. Our new PBS model is simple, inexpensive and widely available to screen out the high risk patients. BioMed Central 2021-10-29 /pmc/articles/PMC8555175/ /pubmed/34715862 http://dx.doi.org/10.1186/s12935-021-02275-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Primary Research Zhang, Yan Shi, Yuanfei Shen, Huafei Shou, Lihong Fang, Qiu Zheng, Xiaolong Zhu, Mingyu Huang, Xin Huang, Jiansong Li, Li Zhou, De Zhu, Lixia Zhu, Jingjing Ye, Xiujin Jin, Jie Xie, Wanzhuo The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma |
title | The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma |
title_full | The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma |
title_fullStr | The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma |
title_full_unstemmed | The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma |
title_short | The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma |
title_sort | value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral t-cell lymphoma |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555175/ https://www.ncbi.nlm.nih.gov/pubmed/34715862 http://dx.doi.org/10.1186/s12935-021-02275-2 |
work_keys_str_mv | AT zhangyan thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT shiyuanfei thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT shenhuafei thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT shoulihong thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT fangqiu thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhengxiaolong thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhumingyu thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT huangxin thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT huangjiansong thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT lili thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhoude thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhulixia thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhujingjing thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT yexiujin thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT jinjie thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT xiewanzhuo thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhangyan valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT shiyuanfei valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT shenhuafei valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT shoulihong valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT fangqiu valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhengxiaolong valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhumingyu valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT huangxin valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT huangjiansong valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT lili valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhoude valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhulixia valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT zhujingjing valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT yexiujin valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT jinjie valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma AT xiewanzhuo valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma |